A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals

Paul Sorum1, Christopher Stein2, Danielle Wales3 and David Pratt4

Abstract
The process of developing and marketing new pharmaceuticals in the United States is driven by a need to maximize returns to shareholders. This results all too often in the production of new medications that are expensive and of marginal value to patients and society. In line with our heightened awareness of the importance of social justice and public health—and in light of our government’s alliance with private companies in bringing us COVID-19 vaccines—we need to reconsider how new pharmaceuticals are developed and distributed. Accordingly, we propose the creation of a new agency of the Food and Drug Administration (FDA) that would direct the whole process. This agency would fund the research and development of high-value medications, closely monitor the clinical studies of these new drugs, and manage their distribution at prices that are value-based, fair, and equitable.

Keywords
drug development, drug industry, costs and cost analysis, health equity, United States food and drug administration

Impetus for Transformation
Health care goods and services, including prescription medications, are simply not equivalent to most marketed products. First, patients’ choices are directed by the advice of their physicians, who order the medications, tests, and procedures expected to provide greatest benefit. Yet, most monetary costs in the United States are covered by private or public insurances—that is, they are borne not by patients but collectively by others in insurance pools or by taxpayers. Second, health care is ultimately a social as well as an individual good. Healthy citizens are happier, more productive, and less burdensome. The public has a major interest in preserving and improving the health of its members while controlling costs. However, like an iceberg, the problems created by the current way medications are developed and marketed in the United States are enormous and often hidden.

Current Problems
These problems result in large part from the need of private pharmaceutical companies to cover costs and maximize returns to shareholders. They obtain lengthy, government-sanctioned monopolies in the form of 20-year patents granted during drug development by the U.S. Patent and Trademark Office and by awards, at the time of Food and Drug Administration (FDA) approval, of five-year market exclusivity (12 for biologics) before a generic can be sold. These companies are also incentivized to take out a series of patents, make minor changes to prolong patents, and even pay generic manufacturers to delay market entry.1–6 Many new pharmaceuticals with promising market potential are either close copies or high-priced specialty drugs rather than innovations with wide benefit.3 Competition incites expensive efforts to influence prescribers directly through office interactions (including providing samples), payments to private physicians involved in drug trials, and financing of medical meetings, as well as indirectly through direct-to-consumer marketing, especially over television.7–10

1Internal Medicine and Pediatrics, Albany Medical College, Albany Medical Center Internal Medicine and Pediatrics, Cohoes, NY, USA
2Management and Health Studies, Siena College, Loudonville, NY, USA
3Internal Medicine and Pediatrics, Albany Medical College, Albany Medical Center Internal Medicine and Pediatrics, Cohoes, NY, USA
4Schenectady County Public Health Services, Schenectady, NY, USA
5Corresponding Author:
Paul Sorum, Albany Medical College Internal Medicine & Pediatrics, 1019 New Loudon Road, Cohoes, NY 12047, USA.
Email: sorump@amc.edu
The involvement of pharmaceutical companies in drug studies can result in distortions of good science, even though journals are making efforts to prevent this. Trials may be allowed to use interim measures not closely linked to desired outcomes, as in the case of aducanumab. Conflicts of interest occur when academic leaders sit on the boards of for-profit companies and when peer reviewers for medical journals have received grants from sponsors of the research. The result may be FDA approval of, and an increase in expenditures for, medications of uncertain value, especially in oncology; this can be aggravated by FDA-accelerated approval. Pharmaceutical companies also engage in expensive U.S. lobbying—estimated at $306,230,000 in 2020—to influence the federal government’s oversight or lack thereof. The lack of central coordination of the development of new drugs can lead to a redundancy of efforts, a waste of resources, and a further increase in costs.

While other wealthy countries face similar problems, their governments have taken actions to control drug prices. The prices of pharmaceuticals in the United States are the highest in the world and are rapidly increasing. This increases the financial burden on U.S. patients—especially with their high out-of-pocket payments for prescription drugs—and decreases their use of prescribed medications. Indeed, in January 2021, Americans rated lowering drug prices as their second highest priority for President Biden and the new Congress.

The Long-Term Solution

Congress should authorize the creation within the FDA of a New Pharmaceuticals Agency, with the current Center for Drug Evaluation and Research as a branch. The Agency would have broad powers (expanding on proposals by Dennis Kucinich and by Adam Gaffney and Joel Lexchin). It would be composed of scientific experts in basic research, clinical medicine, clinical trials, and marketing and advised by representatives from key stakeholders, including pharmaceutical companies, clinicians, pharmacists, and patients. It would work to ensure a more equitable and value-driven process at each stage of drug development and distribution (similar to the goals of Ezekiel Emanuel and Richard Frank). It would institute, in all its details, the plan outlined here. To wit:

- Discovery and innovation. Basic research—mostly performed by academic researchers—would continue to be grant-supported, with Agency encouragement of creative freedom and of the investigation of novel mechanisms of action. Financial support of research and development (R&D) would shift the risk calculations of pharmaceutical companies and enable them to join researchers and the Agency in looking preferentially for drugs that would treat common, hitherto untreated illnesses or conditions or that would significantly advance current treatments, whether by increasing efficacy, reducing side effects, or including previously excluded patients.

- Decision to proceed to development. Researchers, pharmaceutical companies, and Agency members would collaborate to decide what potential new drugs merit further testing in light of their expected costs and their possible benefits to patients and society (including to patients at risk of or suffering from rare disorders). Companies would not be prohibited from developing new drugs on their own with completely private financing, including drugs of lesser benefit, even “me too” drugs. To obtain FDA approval, however, they would have to agree to Agency oversight of testing, production, and distribution (as described below).

- Testing. Clinical trials, whether performed by pharmaceutical companies or by academic institutions, would also be grant-supported (as advocated by John Ioannidis). Going beyond the current use of Data and Safety Monitoring Boards and building on Marcia Angell’s proposal of an Institute for Prescription Drug Trials, Agency members would provide scientific oversight from beginning to end: pre-approving protocols, monitoring progress, approving termination, and ensuring correct reporting of results. This insistence on sound evidence is consistent with the preliminary decision of the Centers for Medicare and Medicaid to pay for aducanumab only in the context of a clinical trial. As further protection against “regulatory capture” of the Agency by pharmaceutical companies, the Phase 3 trials would be run by independent bodies of experts in clinical trials, as proposed by Norin Hadler and others.

- Production. Extending the Operation Warp Speed model, pharmaceutical companies—usually those involved in developing the new drugs—would then produce these drugs under contract from the Agency, which would pay all costs, coordinate the supply of pharmaceutical inputs, and, by concentrating their purchase, generate a strong negotiating position with suppliers. Thereby the Agency would be able to lower costs and limit, although not eliminate, supply chain issues such as shortages, poor quality, or contamination of materials.

- Approval. The FDA would continue its current pre-marketing approval process for new drugs, whether produced by U.S. or foreign companies. This would be facilitated for U.S. drugs by the Agency’s involvement in testing. Their evidence-based development would reduce the risk from potential conflicts of interest within the FDA.

- Distribution and marketing. The Agency would oversee the distribution of these FDA-approved pharmaceuticals to pharmacy chains, private pharmacies, hospitals, and other entities that distribute or administer them. To do this, it would establish its own supply networks or contract with private entities unrelated to pharmaceutical companies. Prices would be calculated both to cover the costs...
of R&D and of distribution and to provide companies with fair profits that reflect the value to patients of each medication (as proposed by Emanuel\(^1\))\(^{19}\)\(^{19}\), the need to motivate companies, and prices in the international market (as in Germany\(^1\)\(^{28}\)). The pharmaceutical companies would not be allowed to have patents on these medications (as has long been advocated by Dean Baker\(^1\)\(^\text{1,50}\)). The importance of this is highlighted by the higher-than-necessary prices charged around the world, amid the pandemic, for vaccines against SARS-CoV-2 that were subsidized by public funds.\(^1\)\(^{51,52}\)

- **Post-distribution surveillance** for effectiveness and side effects. This important but difficult task\(^5\)\(^{3,54}\) is currently performed by FDA committees using data primarily collected “passively,” that is, from adverse events reported by patients and clinicians and by manufacturers.\(^5\)\(^{55,56}\) The FDA also started in 2008 a program of “active” safety surveillance, the Sentinel System, looking for specified adverse events in an increasingly large database of patient records in participating health care systems and insurers.\(^5\)\(^{55,57-59}\) The Agency’s increased role in development and distribution would enable it to expand on both types of surveillance, whether performed internally or contracted to outside researchers. Its centralized database detailing the development and clinical trials of new medications would not only provide key information to the Sentinel System’s active surveillance program,\(^6\)\(^{60}\) but could lead to artificial intelligence algorithms that identify reduced efficacy or serious harms in certain circumstances or populations.\(^6\)\(^{61}\) The Agency could also increase transparency through public accessibility to the timely publication of the follow-up data on effectiveness and side effects.

The plan must take into account the international nature of the pharmaceutical market and of pharmaceutical companies. Only companies that are headquartered in (and, therefore, pay taxes in) the United States would be part of the plan, that is, would be both supported financially and regulated closely. All companies, however, would not only need FDA approval of their drugs for sale and use in the United States (as is required now), but also be subject to the Agency’s control of prices and supervision of distribution.

**Responses to Likely Objections**

Opponents will allege that this plan would decrease incentives for innovation, not stop companies from focusing on high-profit drugs, delay patients’ access to new medications and result in rationing, give the Agency the impossible task of determining “value,” overexpand government’s role, add enormously to the federal budget, use U.S. tax money to pay foreign pharmaceutical company workers, have no more impact than mere regulation of prices, lead to the ex-patriation of American companies,\(^6\)\(^{3,54}\) have limited impact since foreign-based companies have (in total) higher sales than U.S.-based companies,\(^6\)\(^{53}\) and alter but not reduce the influence of politicians and special interests.

In response, even if for-profit companies invest less in R&D if they expect lower profits,\(^3\) much basic research is performed by academics, and innovation is proportionally as great in countries with government-restricted prices.\(^5\)\(^{6,64}\) Government agencies already fund substantial basic research,\(^3\)\(^{6,65}\) and Agency support even of R&D failures would foster more innovation and greater entrepreneurial risk-taking by private companies, including smaller firms and start-ups. Funds distributed to these companies would be designed to shield them from financial failure and keep them in the business of developing new drugs. These funds would incentivize companies to participate in the plan rather than develop drugs on their own, especially since they would still need to accept Agency oversight of clinical trials and distribution. Indeed, with Agency aid and oversight throughout, the process from basic research to distribution should go more smoothly and efficiently. The public would have increased and quicker access to beneficial medications. Other high-income countries use government regulations to restrain drug prices\(^7\)\(^{3,30}\)\(^{78-80}\)\(^{28,30}\)\(^{28-30}\)\(^6\)\(^{60}\), although far less than the regulations proposed here—without any apparent deleterious effects on patient outcomes, as compared to the United States.\(^6\)\(^{66}\) Since the best way to determine “value” is indeed controversial,\(^6\)\(^{67-71}\) the Agency would need to decide on an appropriate but flexible mix of patient and public benefits,\(^7\)\(^2,73\) with help from the independent Institute for Clinical and Economic Review\(^7\)\(^0,74,75\) (similar to the role of the National Institute of Health and Care Excellence in the United Kingdom).

While the Agency would indeed be large and have new responsibilities, its role would be mostly oversight and approval, with the major work performed by the academic researchers, pharmaceutical companies, and distribution enterprises with which it contracts. Already the FDA must approve all drugs produced here and abroad before marketing, and the Centers for Medicare and Medicaid Services plays an even larger role in health care. While the Agency would have a large staff and cover the high costs of R&D and distribution,\(^5\)\(^7\)\(^6,77\) medication prices would be set to cover these costs, which would be lower because of reduced expenditures on pharmaceutical inputs, on utilization management,\(^7\)\(^8\) on intermediaries\(^7\)\(^9\)—especially pharmacy benefit managers,\(^8\)\(^0\) on which the Republicans in Congress put primary blame for high drug prices\(^8\)\(^1\)—and on marketing. Whether the drug R&D supported by taxes is performed here or abroad, taxpayers would benefit from the increased supply of better and affordable mediation and would, in particular, save money from the lower prices of new medications in government-run insurance plans, especially Medicare. Control of final prices alone, without support of R&D, would do little to stimulate the innovation that is of utmost benefit to patients’ health.

U.S. companies would be unlikely to move their headquarters to foreign countries because they would lose the
Agency’s financial support of R&D and production and its protection against the risk of failure. Foreign companies already face price controls in countries other than the United States; their drugs already must receive FDA approval; and the new price controls and regulation of sales in the United States would affect U.S. and foreign companies equally. The Agency’s authority would enable it to negotiate fair but lower prices for those medications made only by companies headquartered abroad.

The choices of where to focus R&D would depend on what the Agency sees as beneficial to patients and society. Currently, for example, the National Institutes of Health HEAL project is funding research to deal with the opioid crisis. The Agency would, therefore, surely face funding pressures from politicians and special interests (in line with Baker’s warnings), even if the pharmaceutical companies, with lower profits at stake, would have less reason to lobby Congress. These pressures can be resisted, to a large degree, by insisting on transparency (as the public also wants) and by relying at all stages on the advice and judgments of independent experts.

**Actions to Take Now**

A wide variety of ways to reduce drug prices have recently been proposed. These include allowing Medicare to negotiate prices for medications, encouraging Medicare — and other insurance providers — to institute payment for value, providing less reward for “me too” drugs and those with limited benefits; restricting maneuvers to extend patent protection; limiting multimedia, direct-to-consumer advertising; rewarding pharmaceutical companies that transform into “public benefit corporations”; setting up a “subscription model” to enable patients to obtain important medications at affordable prices; allowing private not-for-profit companies to produce biosimilar products (such as insulin) and provide them directly to pharmacies at wholesale prices; and using existing, but seldom applied, laws that enable the government to obtain drugs produced at public expense at affordable prices and enable the FDA to switch a drug to over-the-counter status.

Recent suggestions to help patients deal with high prices have included patient assistance programs and medication price guides. Indeed, several bills to reduce high drug prices or mitigate their impact have been introduced in the current Congress. Our plan, however, would offer much greater benefits. With Agency oversight of the whole process and without the need to maximize profits, the newly developed pharmaceuticals would be innovative, more likely to benefit patients and society, priced fairly, and distributed equitably. More affordable medications would improve patients’ health, decrease inequities in health care, and lower costs. Central coordination would also enable greater availability of the data collected during the clinical trials and post-approval surveillance of medications, in line with the National Institutes of Health’s recent call for an expanded sharing of scientific value, citing its value in responding to the COVID-19 pandemic.

The political barriers to change are, of course, enormous, especially to the profound changes proposed here. Even if smaller pharmaceutical companies realize the benefits to them of risk-sharing by the government, the major companies will oppose these changes strenuously with large amounts of money. Nonetheless, is it not time to apply the lessons of our successes and failures in confronting COVID-19 to transforming how pharmaceuticals are developed, tested, and distributed? Is it not time to remind ourselves that health care’s primary purpose is to improve the well-being of patients and society and, accordingly, to institute a process that yields a rational, high-quality, and affordable pipeline of safe, efficacious, and widely available medications? To us, it is past time.

**Declaration of Conflicting Interests**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Wales received salary support from Gilead, Inc., for Project Focus, a hepatitis C screening project.

**Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

**ORCID iDs**

Paul Sorum — https://orcid.org/0000-0003-4009-9343

Danielle Wales — https://orcid.org/0000-0002-4843-7960

**References**

1. Baker D. Financing drug research: what are the issues? Center for Economic and Policy Research. Issue brief, September 22, 2004. https://cepr.net/documents/publications/intellectual_property_2004_09.pdf. Accessed January 10, 2022.

2. Kesselheim A, Avorn J, Sarpawari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858–871. doi:10.1001/jama.2016.11237

3. Congressional Budget Office. Research and Development in the Pharmaceutical Industry. April 2021. https://www.cbo.gov/system/files/2021-04/57025-Rx-RnD.pdf. Accessed January 10, 2022.

4. Becerra X. Comprehensive plan for addressing high drug prices. A report in response to the executive order on competition in the American economy. U.S. Department of Health and Human Services. September 9, 2021. https://aspe.hhs.gov/reports/comprehensive-plan-addressing-high-drug-prices. Accessed January 10, 2022.

5. Blumenthal D, Miller M, Gustafsson L. The U.S. can lower drug prices without sacrificing innovation. Harvard Business Rev. October 1, 2021. https://hbr.org/2021/10/the-u-s-can-
lower-drug-prices-without-sacrificing-innovation. Accessed January 10, 2022.
6. Bloomfield D, Walsh BS, Kesselheim AS. Extending drug monopolies by patenting safe drug use. *JAMA Intern Med.* 2022;182(3):245–246. doi: 10.1001/jamainternmed.2021.7954. Accessed February 11, 2022.
7. Gaffney A, Lexchin JUS. Canadian pharmaceutical Policy Reform Working Group. Healing an ailing pharmaceutical system: prescription for reform for United States and Canada. *Br Med J.* 2018;236:k1039. doi: https://doi.org/10.1136/bmj.k1039. Accessed January 10, 2022.
8. Angell M. Industry-Sponsored clinical research: a broken system. *JAMA.* 2008;300(9):1069–1071. doi: 10.1001/jama.300.9.1069
9. Schwartz LA, Woloshin S. Medical marketing in the United States, 1997–2016. *JAMA.* 2019;321(1):80–96. doi: 10.1001/jama.2018.19320
10. Diekema DS, and the Committee on Bioethics. American Academy of Pediatrics. Health care clinicians and production promotion by industry. *Pediatrics.* 2022;149(4):e2022056549. Accessed April 7, 2022. doi: 10.1542/peds.2022-056549
11. Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, Wolf-Dieter L. The financing of drug trials by pharmaceutical companies and its consequences. Part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. *Dtsch Arztebl Int.* 2010;107(17):295–301.
12. Lexchin J. Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications. *Sci Eng Ethics.* 2012;18(2):247–261. doi:10.1007/s11948-011-9265-3
13. DeAngelis C, Fontanarosa P. Impugning the integrity of medical science: the adverse effects of industry influence. *JAMA.* 2008;299(15):1833–1835. doi: 10.1001/jama.299.15.1833
14. Matheson A. The ICMJE Recommendations and pharmaceutical marketing—strengths, weaknesses and the unsolved problem of attribution in publication. *BMC Med Ethics.* 2016;17:20. doi: 10.1186/s12910-016-0103-7
15. Rupp T, Zuckerman D. Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints. *JAMA Intern Med.* 2017;177(2):276–277. doi: 10.1001/jamainternmed.2016.7761
16. Alexander C, Knopman D, Emerson S, et al. Revisiting FDA approval of aducanumab. *N Engl J Med.* 2021;385(9):769–771. doi:10.1056/NEJMp2110468
17. Becker C. Relationship between academic medicine leaders and industry—time for another look? *JAMA.* 2020;324(18):1833–1834. doi: 10.1001/jama.2020.21021
18. Sachs R. The FDA’s approval of Adubhelm: potential implications across a wide range of health policy issues and stakeholders. *Health Aff Forefront.* June 10, 2021. https://www.healthaffairs.org/do/10.1377/forefront.20210609.921363. Accessed on February 11, 2022.
19. Glass JD, Fournier CN. Unintended consequences of approving unproven treatments—hope, hype, or harm? *JAMA Neurol.* 2022;79(2):117–118. doi: 10.1001/jamaneurol.2021.4193
20. Vokinger KN, Hwang TJ, Glaus CEG, Kesselheim AS. Therapeutic value assessments of novel medicines in the US and Europe, 2018–2019. *JAMA Netw Open.* 2022;5(4):e226479. doi:10.1001/jamaneetworkopen.2022.6479. Accessed April 7, 2022.
21. Fu M, Naci H, Booth C, et al. Real-world use of and spending on new oral targeted cancer drugs in the US, 2011–2018. *JAMA Intern Med.* 2021;181(12):1596–1604. doi:10.1001/jamainternmed.2021.5983
22. Robinson J. Why is aducanumab priced at $56,000 per patient? Lessons for drug-pricing reform. *N Engl J Med.* 2021;385(22):2017–2019. doi:10.1056/NEJMtp2111367
23. Shahzad M, Naci H, Wagner A. Estimated medicare spending on cancer drug indications with a confirmed lack of clinical benefit after US food and drug administration accelerated approval. *JAMA Intern Med.* 2021;181(12):1673–1675. doi: 10.1001/jamainternmed.2021.5989
24. Duffin E. Leading lobbying industries in the U.S. 2020. *Statista.* March 4, 2021. https://www.statista.com/statistics/257364/lobbying-industries-in-the-us/. Accessed January 10, 2022.
25. Wouters O. Lobbying expenditures and campaign contributions by the drug industry in the United States. *JAMA Intern Med.* 2020;189(5):688–697. doi:10.1001/jamainternmed.2020.0146
26. Sanger-Katz M. Democrats’ stumble on drug prices shows power of industry. *New York Times.* The Upshot. September 15, 2021. https://www.nytimes.com/2021/09/15/upshot/democrats-stumble-drug-prices.html?campaign_id=9&emc=edit_tt_20210916&instance_id=40538&nl=themorning&regi_id=90755137&segment_id=69068&tie=1&user_id=22c5fe33121b6022eb44296f5714001. Accessed January 10, 2022.
27. Beaver J, Pazdur R. The wild west of checkpoint inhibitor development. *N Engl J Med.* 2021;386(14):1297–1301. doi: 10.1056/NEJMp2116683. Accessed January 10, 2022.
28. Rodwin M, Gerke S. German Pharmaceutical pricing: lessons for the United States. *Int J Health Serv.* 2022;52(1):146–158. doi:10.1177/00207314211040948
29. Emanuel E, Zhang C, Glickman A, Gudbranson E, DiMagno N, Fli E. Leading lobbying industries in the U.S. 2020. *Statista.* March 4, 2021. https://www.statista.com/statistics/257364/lobbying-industries-in-the-us/. Accessed January 10, 2022.
30. Rodwin M. Common pharmaceutical price and cost controls in the United Kingdom, France, and Germany: lessons for 6 peer countries. *JAMA Intern Med.* 2020;180(11):1510–1517. doi: 10.1001/jamainternmed.2020.4793
31. Rodwin M. Common pharmaceutical price and cost controls in the United Kingdom, France, and Germany: lessons for 6 peer countries. *JAMA Intern Med.* 2020;180(11):1510–1517. doi: 10.1001/jamainternmed.2020.4793
32. Mulcahy A, Whaley C, Tebeka M, Schwarn D, Edem B, Oenelas A. *International Prescription Drug Price Comparisons.* Rand Corporation Research Report. 2021. https://www.rand.org/content/dam/rand/pubs/research_reports/RR2900/RR2956/RAND_RR2956.pdf. Accessed January 10, 2022.
33. So-Yeon K, Polsky D, Segal J, Anderson G. Ultra-expensive drugs and Medicare part D: spending and beneficiary use up sharply. *Health Aff (Millwood).* 2021;40(6):1000–1005. doi:10.1377/hlthaff.2020.00896

34. Zhou T, Liu P, Dhruba SS, et al. Assessment of hypothetical out-of-pocket costs of guideline-recommended medications for the treatment of older adults with multiple chronic conditions, 2009 and 2019. *JAMA Intern Med.* 2022;182(2):185–195. doi:10.1001/jamaipm.2021.7457

35. Carroll A. Even a modest co-payment can cause people to skip drug doses. *New York Times.* The Upshot. November 11, 2019. https://www.nytimes.com/2019/11/11/upshot/drugs-cost-dietabes.html. Accessed January 10, 2022.

36. POLITICO and Harvard T.H. Chan School of Public Health. *The American Public’s Priorities for the New President and Congress.* January 2021. https://cdn1.sph.harvard.edu/wp-content/uploads/sites/94/2021/01/Politico-HSPH-Jan-2021-PollReport.pdf. Accessed January 10, 2022.

37. Kirzinger A, Kearney A, Stokes M, Brodie M. KFF Health tracking poll - may 2021: prescription drug prices top public’s care priorities. *Kaiser Family Foundation.* June 3, 2021. https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2021/. Accessed January 10, 2022.

38. Kucinich D. Free Market Drug Act of 2004. H.R. 5155. 108th Congress, 2d Session, 2004. https://www.congress.gov/108/bills/hr5155/BILLS-108hr5155ih.pdf. Accessed January 10, 2022.

39. Emanuel E. When is the price of a drug unjust? The average lifetime earnings standard. *Health Aff (Millwood).* 2019;38(4):604–612. doi:10.1377/hlthaff.2018.05052

40. Frank R, Emanuel E. Paying for drugs that prove their benefit. *JAMA.* 2021;326(16):1579–1580. doi:10.1001/jama.2021.18308

41. Ioannidis J. Why most clinical research is not useful. *PloS Med.* 2016;13(6):e1002049. doi:10.1371/journal.pmed.1002049. Accessed January 10, 2022.

42. Evans SR. Independent oversight of clinical trials through data and safety monitoring boards. *JAMA Evid.* 2022;1(1). doi:10.1056/EVIDctw2100005. Accessed February 11, 2022.

43. Sachs R. Understanding Medicare’s adulthood coverage decision. *Health Aff Forefront.* January 12, 2022. https://www.healthaffairs.org/do/10.1377/forefront.2020112.876687. Accessed February 11, 2022.

44. Hadler N. American Healthcare racket: monopolies, oligopolies, cartels and kindred plunderbunds. *The Health Care Blog.* November 25, 2016. https://thehealthcareblog.com/blog/2016/11/25/american-healthcare-rackets-monopolies-oligopolies-cartels-and-kindred-plunderbunds/. Accessed January 10, 2022.

45. Hadler N. Health assurance and the communitarian ethic. *J Occup Environ Med.* 2008;50(10):1096–1098. doi:10.1097/JOM.0b013e318188b91e

46. Naudet F, Siebert M, Boussageon R, Cristea I, Tumer E. An open science pathway for drug marketing authorization—registered drug approval. *PLoS Med.* 2021;18(8):e1008726. https://doi.org/10.1371/journal.pmed.1003726. Accessed January 10, 2022. doi:10.1371/journal.pmed.1003726

47. Jureidini J, McHenry LB. The illusion of evidence based medicine. *Br Med J.* 2022;376:o702. http://dx.doi.org/10.1136/bmj.o702. Accessed April 7, 2022.

48. Edney A. Big Pharma’s little secret: drug cross-contamination is rampant. *Bloomberg Businessweek.* July 26, 2021. https://www.bloomberg.com/news/articles/2021-07-26/big-pharma-s-little-secret-drug-cross-contamination-is-rampant. Accessed January 10, 2022.

49. Stolberg S, Kaplan S. Biden chooses Robert Califf to lead F.D.A., despite drug industry ties. *New York Times.* November 12, 2021. https://www.nytimes.com/2021/11/12/us/politics/robert-califf-fda.html?searchResultPosition=1. Accessed January 10, 2022.

50. Baker D. The Future of the Pharmaceutical Industry: Beyond Government-Granted Monopolies. Center for Economic and Policy Research. Working Paper. March 6, 2019. https://cepr.net/images/stories/reports/pharma-industry-2019-03.pdf. Accessed January 10, 2022.

51. Light D, Lexchin J. The costs of coronavirus vaccines and their pricing. *J R Soc Med.* 2021;114(1):502–504. doi:10.1177/0141076821105006

52. Murphy T. COVID-19 vaccine sales push Moderna to $12B profit in 2021. *Medscape.* February 24, 2022. https://www.medscape.com/viewarticle/969081?uac=41490AG&fa=false&result=1&ssost盈=true&implID=4045574&src=mkm_covid_update_220224_MSCPEDIT. Accessed February 24, 2022.

53. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. *Drug Saf.* 2006;29(5):385–396. doi:10.2165/00002018-200629050-00003

54. Gibbons RD, Amatya AK, Brown CH, et al. Post-approval drug safety surveillance. *Anna Rev Public Health.* 2010;31:419–437. doi:10.1146/annurev.publhealth.012809.103649

55. U.S. Food and Drug Administration. The Sentinel Initiative: Access to Electronic Healthcare Data for More Than 25 Million Lives. July 2010. https://www.fda.gov/media/79652/download. Accessed April 7, 2022.

56. U.S Food and Drug Administration. Postmarketing surveillance programs. https://www.fda.gov/drugs/surveillance/postmarketing-surveillance-programs. Accessed March 23, 2022.

57. Platt R, Brown JS, Robb M, et al. The FDA sentinel initiative — and evolving national resources. *N Engl J Med.* 2018;379(22):2091–2093. doi:10.1056/NEJMfip1809643

58. U.S. Food and Drug Administration. Sentinel System: Five-Year Strategy 2019–2023. January 2019. https://www.fda.gov/media/120333/download. Accessed April 7, 2022.

59. Sentinel System website. https://www.sentinelinitiative.org/. Accessed April 7, 2022.

60. Campbell RR, Spehar AM, French DD. Proactive postmarketing surveillance: overview and lessons learned from medication safety research in the Veterans Health Administration. 2008. https://www.ahrq.gov/downloads/pub/advances2/vol1/Advances-Campbell-R_106.pdf. Accessed March 23, 2022.

61. Alomar M, Tawﬁq AM, Hassan N, Palaiian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the
future. Ther Adv Drug Saf. 2020;11:1–11. doi:10.1177/204209820938595
62. Ricks D. The risks of government negotiation of drug prices. Boston Globe. Opinion. October 25, 2021. https://www.bostonglobe.com/2021/10/25/opinion/risks-government-negotiation-drug-prices/. Accessed January 10, 2022.
63. Drug Discovery & Development. Pharma 50: the 50 largest pharmaceutical companies in the world. https://www.drugdiscoverytrends.com/pharma-50-the-50-largest-pharmaceutical-companies-in-the-world/. Accessed January 10, 2022.
64. Keyhani S, Wang S, Hebert P, Carpenter D, Anderson G. US Pharmaceutical innovation in an international context. Am J Public Health. 2010;100(6):1075–1080. doi:10.2105/AJPH.2009.178491
65. Cleary E G, Beierlein JM, Khanuga NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010–2016. Proc Natl Acad Sci U S A. 2018;115(10):2329–2334. doi:10.1073/pnas.1715368115
66. Schneider E, Shah A, Doty M, Tikkanen R, Fields K, Williams R. Mirror, mirror 2021: reflecting poorly. Health care in the U.S. compared to other high-income countries. Commonwealth Fund Reports. August 4, 2021. https://www.commonwealthfund.org/publications/fund-reports/2021/au/gl/mirror-mirror-2021-reflecting-poorly.
67. Kaltenboeck A, Bach PB. Value-based pricing for drugs: themes and variations. JAMA. 2018;329(21):2165–2166. doi:10.1001/jama.2018.4871
68. Kaltenboeck A, Calsyn M, Frederi GWJ, et al., on behalf of the Consortium for Value-Based Drug Access. Grounding value-based drug pricing in population health. Clin Pharmacol Ther. 2020;107(6):1290–1292. doi:10.1002/cpt.1741
69. Mattke S. How current cost-effectiveness analyses distort drug development. Health Aff Blog. November 15, 2021. https://www.healthaffairs.org/do/10.1377/forefront.20211115.976166. Accessed March 5, 2022.
70. Neumann PJ, Cohen JT, Ollendorf DA. Drug-pricing debate—should cost-effectiveness analysis be used now to price pharmaceuticals? N Engl J Med. 2021;385(21):1923–1924. doi:10.1056/NEJMp2113323
71. Westrich K, Dubois RW. Value assessment’s “leaky bucket” problem needs to be addressed. Health Aff Forefront. January 13, 2022. https://www.healthaffairs.org/do/10.1377/forefront.20220111.955206. Accessed February 11, 2022.
72. Lurie P, Sharfstein JM. Product approval and public health at the US food and drug administration. JAMA. 2021;326(24):2469–2470. doi:10.1001/jama.2021.22354
73. Lakdawalla DN, Linthicum MT, Phelps C. How COVID can help us refocus on the how and why of value assessment. Health Aff Blog. October 21, 2021. https://www.healthaffairs.org/do/10.1377/forefront.20211019.97446. Accessed March 5, 2022.
74. Neumann PJ, Ollendorf DA, Cohen JO. Value-based drug pricing in the Biden era. Health Serv Res. 2021;56(6):1093–1099. doi:10.1111/1475-6773.13686
75. Emond S. Fair prices should lead to fair access: why is the grand bargain so hard? Health Aff Blog. November 2, 2021. https://www.healthaffairs.org/do/10.1377/forefront.202111029.662741. Accessed March 5, 2022.
76. Wouters O, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323(9):844–853. doi:10.1001/jama.2020.1166
77. Schlander M, Hernandez-Villafuerte K, Cheng C-Y, Mestre-Ferrandiz J, Baumann M. How much does it cost to research and develop a new drug? A systematic review and assessment. PharmacoEconomics. 2021;39(11):1243–1269. doi:10.1007/s40273-021-01065-y
78. Howell S, Yin P, Robinson J. Quantifying the economic burden of drug utilization management on payers, manufacturers, physicians, and patients. Health Aff (Millwood). 2011;40(8):1206–1214. doi:10.1377/hlthaff.2011.0036
79. Van Nuys K, Ribero R, Ryan M, Sood N. Estimation of the share of net expenditures on insulin captured by US manufacturers, wholesalers, pharmacy benefit managers, pharmacies, and health plans from 2014 to 2018. JAMA Health Forum. 2021;2(11):e213409. doi:10.1001/jamahealthforum.2021.3409. Accessed January 10, 2022.
80. Royce T, Schenkel C, Kirkwood K, Levit L, Levit K, Kircher S. Impact of pharmacy benefit managers on oncology practices and patients. JCO Oncol Pract. 2020;16(5):276–284. doi:10.1200/JOP.19.00606
81. Minority Staff, Committee on Oversight and Reform, U.S. House of Representatives. A View from Congress: Role of Pharmacy Benefit Managers in Pharmaceutical Markets. Report. December 10, 2021. https://republicans-oversight.house.gov/wp-content/uploads/2021/12/PBM-Report-12102021.pdf. Accessed January 10, 2022.
82. National Institutes of Health. 2021. HEAL Initiative. https://heal.nih.gov/about. Accessed January 10, 2022.
83. Azad TD, Plotz CF, Gielen AC, Sharpstein JM. Assessment of public opinion on transparency at the US Food and Drug Administration. JAMA Newt Open. 2022;5(2):e220026. doi:10.1001/jamanetworkopen.2022.0026. Accessed February 19, 2022.
84. Alexander C, Ballreich J, Socal M, et al. Reducing branded prescription drug prices: a review of policy options. Pharmacotherapy. 2017;37(11):1469–1478. doi:10.1002/phar.2013
85. Conti R, Frank R, Gruber J. Regulating drug prices while increasing innovation. N Engl J Med. 2021;385(21):1921–1923. doi:10.1056/NEJMp2113764
86. Mazucato M, Lishi Li H. A market shaping approach for the bio-pharmaceutical industry: governing innovation towards the public interest. J Law Med Ethics. 2021;49(1):39–49. doi:10.1017/jme.2021.8
87. Gavulic K, Dusetzin S. Prescription drug priorities under the new administration. J Health Polit Policy Law. 2021;46(4):599–609. doi:10.1215/03636878-8970810
88. Kesselheim AS, Hwang T, Jerry Avorn J. Paying for prescribing drugs in the new administration. JAMA. 2021;325(9):819–820. doi:10.1001/jama.2021.0009
89. Martin K. Policymakers’ attention turns to drug patents in the debate on prices. Commonwealth Fund Blog. October 7, 2021. https://www.commonwealthfund.org/blog/2021/policymakers-
attention-turns-drug-patents-debate-prices. Accessed January 11, 2022.
90. Feldman R. It’s the patents, stupid—why drugs cost so much in the U.S. Interview by S. Seervai. Commonwealth Fund. The Dose. February 25, 2022. https://www.commonwealthfund.org/publications/podcast/2022/feb/its-the-patents-stupid-why-drugs-cost-so-much-in-us. Accessed March 5, 2022.
91. Businesswire. Veeva becomes first public company to convert to a Public Benefit Corporation. January 14, 2021. https://www.businesswire.com/news/home/20210114005967/en/Veeva-Becomes-First-Public-Company-to-Convert-to-a-Public-Benefit-Corporation. Accessed January 11, 2022.
92. Gee RE. Louisiana’s journey toward eliminating hepatitis C. Health Aff Blog. April 1, 2019. https://www.healthaffairs.org/do/10.1377/forefront.20190327.603623/full/. Accessed March 5, 2022.
93. Sharfstein JM, Killelea A, Dangerfield D. Long-acting cabotegravir for HIV prevention: issues of access, cost, and equity. JAMA. 2022;327(10):921–922. Accessed February 14, 2022.
94. Dafny LS. A radical treatment for insulin pricing. N Engl J Med. 2022. doi:10.1056/NEJMp2203001. Accessed April 7, 2022.
95. Kapczynski A. Realizing public rights through government patent use. Amer J Law Med Ethics. 2021;49(2021):34–38. doi:10.1017/jme.2021.7
96. Engelberg AB, Avorn J, Kesselheim AS. A new way to contain unaffordable medication costs—exercising the government’s existing rights. NEJM. 2022;386(12):1104–1106. doi:10.1056/NEJMp22117102. Accessed February 11, 2022.
97. Cook-Deegan R, Kesselheim AS, Sarpatwari A. Updating the bayh-dole act: march-in rights and transparency. Health Aff Blog. March 5, 2022. doi:10.1377/forefront.20210331.198909. Accessed April 7, 2022.
98. Feldman WB, Avorn J, Kesselheim AS. Switching to over-the-counter availability of rescue inhalers for asthma. JAMA. 2022;327(11):1021–1022. doi:10.1001/jama.2022.1160. Accessed February 21, 2022.
99. Vertinsky L. Exercising march-in rights would make biomedical public-private partnerships stronger. Health Aff Forefront. April 4, 2022. https://www.healthaffairs.org/do/10.1377/forefront.20220331.198909. Accessed April 7, 2022.
100. Sinha MS, Kesselheim AS, Robertson CT. Patient assistance programs and the anti-kickback statute: charting a pathway forward. JAMA. 2022;327(13):1231–1232. doi:10.1001/jama.2022.2043. Accessed March 10, 2022.
101. Feldman R, Feldman N, Seoane-Vasquez E. A patient price guide for prescription medication. Ann Intern Med. Published online March 22, 2022. doi:10.7326/M21-4755. Accessed March 22, 2022.
102. LaRosa J, Slifer E. Key proposals of drug pricing proposals. Commonwealth Fund. April 26, 2021. https://www.commonwealthfund.org/publications/2021/apr/key-provisions-drug-pricing-proposals. Accessed January 11, 2022.
103. Majority Staff, Committee on Oversight and Reform, U.S. House of Representatives. Drug Pricing Investigation. Report. December 10, 2021. https://oversight.house.gov/sites/democrats.oversight.house.gov/files/DRUG%20PRICING%20REPORT%20WITH%20APPENDIX%20v3.pdf. Accessed January 11, 2022.
104. Sachs RE, Kyle MA. Step therapy’s balancing act—protecting patients while addressing high prices. N Engl J Med. 2022;386(10):901–904. doi:10.1056/NEJMp2117582
105. Essien U, Dusetzina S, Gellad W. A policy for reducing health disparities—achieving pharmacoequity. JAMA. 2021;326(18):1793–1794. doi:10.1001/jama.2021.17764
106. Egilman A, Kapczynski A, McCarthy M, et al. Transparency of regulatory data across the European medicines agency, health Canada, and the US food and drug administration. J Law Med Ethics. 2021;49(3):456–485. doi:10.1017/jme.2021.67
107. Jorgenson L, Wolinetz C, Collins F. Incentivizing a new culture of data stewardship: the NIH policy for data management and sharing. JAMA. 2021;326(22):2259–2260. doi:10.1001/jama.2021.20489

Author Biographies

Paul Sorum, M.D., Ph.D., is a Professor Emeritus of Internal Medicine and Pediatrics at Albany Medical College, Albany, New York. He received his M.D. from the University of North Carolina at Chapel Hill in 1980 and did his residency in internal medicine and pediatrics at North Carolina Memorial Hospital and Albany Medical Center. As a faculty member at Albany Medical College, he practiced primary care for children and adults and taught medical students and residents. He has published multiple studies on health-related judgment and decision-making, in collaboration with psychologists in the United States and France, as well as on the treatment of acute otitis media and sinusitis. He has also published articles on the French health care system and on the desirability of single-payer health care in the United States, and he has been active in Physicians for a National Health Program. He is on the medical board of, and has led teams to, the Engeye Health Clinic in rural Uganda and is a consultant for the Better Evidence program of Ariadne Labs.

Christopher Stein, Ph.D., is an Assistant Professor of Management at Siena College, Loudonville, New York, in the departments of Management and Health Studies. He has published on entrepreneurship, organizational justice, and business ethics in journals such as Human Resource Management Review, for the United Nations Principles of Responsible Management, and in Springer collected handbooks. His graduate work in philosophy was at Colorado State University, Fort Collins, Colorado, and he received a Ph.D. in organizational behavior from the University of Central Florida, Orlando, Florida, in 2021.

Danielle Wales, M.D., M.P.H., is an Associate Professor of Internal Medicine and Pediatrics at Albany Medical College, Albany, New York. She received her M.P.H. from the University at Albany in 2009 and her M.D. from
Albany Medical College in 2010. She did her residency in internal medicine and pediatrics at Albany Medical Center. She is an academic primary care physician, practicing in Cohoes, New York. She previously worked as a pediatric hospitalist in Fishersville, Virginia. Her publications have discussed Tdap uptake in pregnant patients, COVID-19 vaccine hesitancy, and the contribution of medical students to the compassionate care of COVID-19 patients. Her research interests include primary care, preventive medicine, immunizations, and quality improvement.

David Pratt, M.D, M.P.H, is a private consultant in public health, palliative care, and preventive medicine. He received his M.D. from Tufts in 1971, did a pulmonary fellowship at the University of Colorado, and received his M.P.H. from the University at Albany in 2007. During his career, he has been part of the team that eradicated smallpox around the world; a faculty member at Bassett Hospital in Cooperstown, New York (1978-1992); the medical director of GE Energy (1995-2007); and the Commissioner of Health of Schenectady County (2009-2012). His publications range from studies of environmental pollutants to quality improvement projects. He is an expert on immunizations and an active proponent of Aid in Dying legislation. He is currently Vice-Chair of the Board of Directors of MVP Health Plan, a regional not-for-profit health insurance company.